VEGFA and neoplasm: Fruquintinib, an orally bioavailable small‐molecule tyrosine kinase inhibitor (TKI) with picomolar affinity for vascular endothelial growth factor (VEGF) receptors 1, 2, and 3, disrupts tumor angiogenesis and growth by blocking VEGF‐dependent phosphorylation and downstream signaling, thereby impairing endothelial cell proliferation, migration, and tube formation [6, 7].